Table 3.
Demographics
| Succinylcholine (N = 200) |
Rocuronium (N = 201) |
Registry (N = 147) |
|
|---|---|---|---|
| Age (years) | 60 ± 16 | 63 ± 14 | 59 ± 16 |
| Sex (m:f) | 114:86 | 112:89 | 94:54 |
| Height (cm) | 170 ± 8 | 170 ± 9 | 171 ± 10 |
| Weight (kg) | 73 ± 15 | 74 ± 19 | 74 ± 11 |
| Apache II Score | 21 ± 7 | 22 ± 7 | 21 ± 6 |
| Underlying COPD | 32 (16%) | 30 (15%) | 27 (13%) |
| 28-day mortality | 73 (37%) | 82 (41%) | 53 (36%) |
| Indication for intubation | |||
| Respiratory failure | 134 (67%) | 130 (65%) | 91 (62%) |
| Neurology | 42 (21%) | 50 (25%) | 41 (28%) |
| Shock | 24 (12%) | 21 (10%) | 15 (10%) |
| Non-invasive ventilation prior to intubation | 93 (47%) | 85 (43%) | 62 (42%) |
| Induction agent | |||
| Propofol | 101 (50%) | 94 (47%) | 47 (32%) |
| Etomidate | 99 (50%) | 107 (53%) | 67 (46%) |
| Other | 33 (22%) | ||
| Neuromuscular blocking agent | |||
| Succinylcholine | 78 (53%) | ||
| Rocuronium | 44 (30%) | ||
| Other | 25 (17%) |
The registry includes patients who were intubated while the trial was recruiting but were not included in the trial due to the unavailability of a study physician (n = 132) or had to be excluded from the trial due to dual inclusion (n = 15).
The observed 28-day mortality corresponds to the expected mortality as APACHE II scores of 21 and 22 predict a mortality of approximately 39% and 42% respectively [10]. COPD, chronic obstructive pulmonary disease.